Sleep disorder market seen topping $58 billion by 2030

The global sleep disorder market is projected to expand rapidly through 2030 as insomnia, sleep apnea and related conditions drive demand for diagnostics, treatments and digital health tools. The Business Research Company says the market could surpass $58 billion by 2030, with North America and the U.S. leading growth.

Why it matters: - Sleep disorders are moving from a niche care category to a larger healthcare market as diagnosis, treatment and monitoring become more common. - The market’s projected growth reflects rising demand for sleep clinics, home testing, digital therapeutics and non-drug treatment options. - The report says the sleep disorder market could reach more than $58 billion by 2030, making it a meaningful slice of the broader sleep and healthcare services markets.

What happened: - The Business Research Company published its Sleep Disorder Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report projects the global sleep disorder market will grow at about 12% annually through 2030. - The market is forecast to top $58 billion by 2030. - The broader sleep market is projected to reach about $166 billion by 2030. - The report says sleep disorders will account for close to 0.5% of the healthcare services industry by 2030, with that industry forecast at $11,335 billion.

The details: - Insomnia is expected to be the largest segment by 2030, at 36% of market revenue or about $21 billion. - Growth in insomnia is tied to demand for cognitive behavioral therapy, non-drug interventions, prescription and over-the-counter sleep aids, and personalized care. - The report identifies polysomnography, home sleep testing, actigraphy, sleep diaries, and questionnaires as major diagnostic methods. - Treatment categories include cognitive behavioral therapy, medication therapy, psychiatric treatment and behavioral treatment. - Distribution channels include retail pharmacies, online sales and hospital pharmacies. - End users include hospitals and sleep centers, home care settings and academic institutions. - North America is projected to remain the largest regional market in 2030 at $20 billion, up from $12 billion in 2025. - The U.S. is forecast to lead country-level sales at $18 billion in 2030, up from $11 billion in 2025. - The report points to insomnia, sleep apnea, restless legs syndrome, narcolepsy and circadian rhythm disorders as the biggest growth contributors between 2025 and 2030. - Those five segments are expected to add more than $25 billion in combined market value over that period. - Eli Lilly and Company held the top global market position in 2025 with a 4% share. - The top 10 firms captured 21% of total revenue in 2025, showing a moderately fragmented market. - The leading companies named include Jazz Pharmaceuticals, ResMed, Sanofi, Takeda, Harmony Biosciences, Otsuka, Merck & Co., Teva and UCB. - The report also lists major suppliers such as Merck KGaA, Thermo Fisher Scientific, Lonza, Sartorius, Cytiva, Evonik, BASF, Ashland and Croda. - Major distributors named in the report include McKesson, Cencora, Cardinal Health, Phoenix Pharma, Medipal, Zuellig Pharma and Sinopharm. - End users named in the report include Eisai, Idorsia, Jazz Pharmaceuticals, Takeda, Pfizer, Sanofi, Johnson & Johnson, Cleveland Clinic, Mayo Clinic, Stanford Health Care and Massachusetts General Hospital. - The report says newer non-drug treatments are gaining traction, including electrical vestibular nerve stimulation. - In October 2024, Neurovalens Ltd. launched modius sleep, an FDA-cleared non-invasive headset that uses VeNS technology to help regulate circadian rhythms and improve sleep patterns. - The device is designed to help users fall asleep faster and sleep longer without medication.

Between the lines: - The report frames sleep disorder care as an area where chronic disease management, consumer wellness and digital health are converging. - Rising rates of obesity, diabetes, cardiovascular disease, anxiety and depression are increasing demand for sleep evaluation and ongoing therapy. - The report says awareness campaigns, employer wellness programs and digital platforms are also helping expand the market. - That mix suggests growth is coming not only from medical need, but also from broader acceptance of sleep as a core health metric. - The market remains competitive, but high regulatory hurdles and clinical validation requirements limit easy entry.

What's next: - The Business Research Company expects growth to continue through 2030 as providers expand sleep services and technology firms push new diagnostics and therapies. - Future gains are likely to come from AI-driven sleep analysis, personalized care models and partnerships between healthcare providers and technology companies. - The report says collaboration, product innovation and geographic expansion will shape the next phase of competition. - Request a free sample of the sleep disorder market report - Access the detailed sleep disorder market report

The bottom line: - Sleep disorder care is becoming a faster-growing and more diversified healthcare market, led by insomnia, U.S. demand and a shift toward digital and drug-free treatment options.